GO:0034123 positive regulation of toll-like receptor signaling pathway: Immune Amplification, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0034123 describes any process that activates or increases the frequency, rate, or extent of toll-like receptor (TLR) signaling, a central innate immune sensing cascade.
• Positive regulation of TLR signaling is essential for rapid antimicrobial and inflammatory responses, but must be tightly balanced to avoid immunopathology.
• Key positive regulators include TLR adaptors (MyD88, TRIF, TIRAP, TRAM), kinases (IRAK1/4, TBK1, IKKε), and transcription factors such as IRF-7 that amplify type I interferon responses.
• Dysregulated positive regulation contributes to inflammatory diseases, myeloproliferative neoplasms, and potentially autoimmune conditions.
• CRISPR-based knockout, knock-in, and overexpression models enable causal dissection of positive regulators in immune cells and hematopoietic progenitors.
• Functional genomics screens combined with bioinformatics can identify novel amplifiers of TLR signaling for therapeutic targeting.
Description
Toll-like receptors (TLRs) are germline-encoded pattern recognition receptors that detect conserved microbial molecules and initiate innate immune signaling. The GO term GO:0034123, positive regulation of toll-like receptor signaling pathway, captures the set of biological processes that enhance the magnitude or duration of TLR signal transduction. This term is critical for understanding how the immune system amplifies danger signals to mount effective antimicrobial responses while avoiding excessive inflammation. Positive regulation of TLR signaling is not a single molecular event but a network of adaptor recruitment, kinase activation, ubiquitination, and transcriptional amplification steps. For example, the transcription factor IRF-7 acts as a master regulator that amplifies type I interferon production downstream of TLR7/9, a classic positive feedback loop. In hematopoietic stem and progenitor cells, TLR signaling influences proliferation and differentiation, linking innate immune activation to hematopoiesis. Researchers study GO:0034123 to identify therapeutic targets for inflammatory diseases, to understand host-pathogen interactions, and to engineer immune cells with tuned responsiveness. The term is also relevant in comparative immunology, as TLR signaling components show distinct evolutionary patterns across species.
positive regulation of toll-like receptor signaling pathway At A Glance
| GO ID | GO:0034123 |
|---|---|
| GO term | positive regulation of toll-like receptor signaling pathway |
| Ontology | biological_process |
| Synonym | positive regulation of TLR signaling pathway; positive regulation of toll-like receptor signalling pathway |
| Major function | Amplification of TLR-mediated innate immune signaling, leading to enhanced NF-κB, MAPK, and IRF activation |
| Key adaptors | MyD88, TIRAP, TRIF, TRAM |
| Key kinases | IRAK1, IRAK4, TBK1, IKKε |
| Key transcription factors | NF-κB, AP-1, IRF-7 |
| Related processes | Innate immunity, inflammatory response, cytokine production |
What Is GO:0034123?
GO:0034123 (positive regulation of toll-like receptor signaling pathway) is defined by QuickGO as any process that activates or increases the frequency, rate, or extent of toll-like receptor signaling pathway. In other words, it encompasses molecular events that amplify TLR-driven signal transduction, leading to enhanced downstream responses such as NF-κB activation, interferon production, and inflammatory cytokine secretion.
Why Is positive regulation of toll-like receptor signaling pathway Important in Cell Biology?
Positive regulation of TLR signaling is a double-edged sword: it is required for effective host defense against pathogens, but excessive or prolonged activation drives chronic inflammation and tissue damage. Understanding GO:0034123 helps researchers identify molecular brakes and accelerators of innate immunity, with implications for vaccine adjuvants, anti-inflammatory drugs, and cancer immunotherapy.
• Enables rapid amplification of antimicrobial responses upon pathogen detection.
• Controls the magnitude of type I interferon production via IRF-7 feedback.
• Dysregulation leads to excessive TNF-α in myeloproliferative neoplasms.
• Influences hematopoietic stem and progenitor cell fate decisions.
• Provides targets for vaccine adjuvants that enhance TLR signaling.
• Contributes to autoimmune and autoinflammatory disease pathogenesis.
• Shapes evolutionary adaptation of immune genes in vertebrates.
• Links microbiome signals to neutrophil ageing and immune homeostasis.
• Offers opportunities for CRISPR-based functional genomics in immune cells.
• Guides development of TLR-targeted therapeutics for infectious and inflammatory diseases.
What Happens During positive regulation of toll-like receptor signaling pathway?
Ligand-induced receptor dimerization and adaptor recruitment
In simple terms: When a microbe is detected, TLRs pair up and recruit helper proteins to start the alarm.
TLR activation begins with ligand binding, which induces receptor dimerization and conformational changes that recruit TIR-domain-containing adaptors such as MyD88, TIRAP, TRIF, and TRAM. Positive regulation at this stage can occur through increased adaptor availability, post-translational modifications that enhance adaptor affinity, or co-receptor interactions that stabilize the signaling complex.
IRAK kinase activation and ubiquitin-dependent signaling
In simple terms: Helper proteins activate kinases that add ubiquitin tags, amplifying the signal.
MyD88 recruits IRAK4 and IRAK1, leading to their phosphorylation and activation. TRAF6, an E3 ubiquitin ligase, then catalyzes K63-linked polyubiquitination of itself and other substrates, which serves as a scaffold for downstream kinase complexes. Positive regulation can be achieved by enhancing IRAK activity or by deubiquitinase inhibition that preserves ubiquitin chains.
TAK1 complex activation and NF-κB/MAPK amplification
In simple terms: A central kinase complex turns on master switches for inflammation.
The TAK1 complex (TAK1, TAB1, TAB2/3) is activated downstream of ubiquitin scaffolds, leading to phosphorylation of IKKβ and MAPK kinases. This results in NF-κB nuclear translocation and AP-1 activation, driving pro-inflammatory cytokine transcription. Positive regulation includes enhanced TAK1 activity or reduced negative feedback by phosphatases such as A20.
TBK1/IKKε activation and IRF-dependent interferon induction
In simple terms: Another branch triggers antiviral interferon genes through IRF proteins.
TRIF-dependent signaling activates TBK1 and IKKε, which phosphorylate IRF3 and IRF7. IRF-7 is a master regulator that amplifies type I interferon gene expression, creating a positive feedback loop essential for antiviral immunity. Positive regulation of this branch can occur through enhanced TBK1 activity or increased IRF-7 expression.
Transcriptional and post-transcriptional feedback amplification
In simple terms: The response can boost itself by making more signaling components.
TLR signaling induces expression of positive regulators such as IRF-7, which further amplifies interferon production. Additionally, microRNAs and RNA-binding proteins can stabilize positive regulator mRNAs, while negative regulators like A20 are downregulated, collectively enhancing pathway output.
Key Genes Involved in GO:0034123 positive regulation of toll-like receptor signaling pathway
The following genes and proteins are central to positive regulation of TLR signaling, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MYD88 | Adaptor for all TLRs except TLR3; recruits IRAK kinases | Knockout models show impaired inflammatory signaling |
| TIRAP | Bridges TLR2/4 to MyD88 | Target for modulating TLR2/4 responses |
| TRIF | Adaptor for TLR3/4; activates TBK1/IRF3 | Key for antiviral interferon induction |
| TRAM | Bridges TLR4 to TRIF | Regulates TLR4 endosomal signaling |
| IRAK4 | Kinase that activates IRAK1 | Essential for MyD88-dependent signaling |
| IRAK1 | Kinase downstream of IRAK4; activates TRAF6 | Amplifies NF-κB and MAPK |
| TRAF6 | E3 ubiquitin ligase; K63 ubiquitination | Central amplifier of TLR signaling |
| TAK1 | Kinase activating IKK and MAPK | Hub for inflammatory gene expression |
| IKKβ | Phosphorylates IκBα, releasing NF-κB | Target for anti-inflammatory drugs |
| TBK1 | Phosphorylates IRF3/7 | Critical for type I interferon response |
| IKKε | Phosphorylates IRF3/7 | Amplifies antiviral signaling |
| IRF7 | Master transcription factor for type I IFN | Positive feedback amplifier |
| NFKB1 | Transcription factor for pro-inflammatory cytokines | Central to TLR-induced inflammation |
| TNF | Pro-inflammatory cytokine induced by TLR signaling | Excessive in myeloproliferative neoplasms |
| A20 (TNFAIP3) | Negative regulator; deubiquitinase | Loss leads to excessive TLR signaling |
| SOCS1 | Negative regulator of TLR signaling | Controls inflammatory magnitude |
| IRAK3 | Negative regulator of IRAK1 | Modulates TLR responsiveness |
How Is positive regulation of toll-like receptor signaling pathway Regulated?
Positive regulation of TLR signaling is itself tightly regulated by negative feedback loops to prevent immunopathology. For example, A20 (TNFAIP3) deubiquitinates TRAF6 and inhibits NF-κB activation, while SOCS1 targets IRAK1 for degradation. In myeloproliferative neoplasms, defective negative regulation leads to excessive TNF-α production, highlighting the importance of balanced control. Additionally, the microbiome influences neutrophil ageing through TLR signaling, demonstrating environmental modulation.
positive regulation of toll-like receptor signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TNFAIP3 (A20) | Autoinflammatory disease, lymphoma | Knockout mice or cell lines |
| MYD88 | Infectious susceptibility, B-cell malignancies | Conditional knockout |
| IRF7 | Severe viral infections | Knockout or overexpression |
| TNF | Myeloproliferative neoplasm | Point mutation knock-in |
| IRAK4 | Immunodeficiency | Knockout iPSCs |
Inflammatory and autoimmune diseases
Excessive positive regulation of TLR signaling contributes to chronic inflammation and autoimmune pathology. For instance, loss of negative regulators such as A20 results in sustained NF-κB activation and increased pro-inflammatory cytokines.
Myeloproliferative neoplasms
Defective negative regulation of TLR signaling leads to excessive TNF-α in myeloproliferative neoplasm, suggesting that unchecked positive regulation drives disease progression.
Infectious diseases
Pathogens can exploit or subvert TLR signaling; understanding positive regulation helps design adjuvants and antivirals. IRF-7-dependent amplification is crucial for type I interferon responses against viruses.
Hematopoietic disorders
TLR signaling in hematopoietic stem and progenitor cells influences their proliferation and differentiation, linking inflammation to blood disorders.
From positive regulation of toll-like receptor signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X positively regulate TLR signaling? | CRISPR knockout in macrophage cell line |
| Does a point mutation in gene Y alter TLR amplification? | Point mutation knock-in via HDR |
| Does overexpression of gene Z enhance interferon response? | Lentiviral overexpression in dendritic cells |
| Which domains of adaptor protein are required for positive regulation? | Domain-specific knock-in or deletion |
| Can we identify novel positive regulators via screens? | CRISPR library screening in TLR reporter cells |
| How does gene W affect TLR signaling in primary immune cells? | Knockout in primary hematopoietic stem cells |
How to Study the positive regulation of toll-like receptor signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss-of-function effects on TLR signaling | Identify positive regulators |
| RNA-seq | Transcriptional changes after TLR activation | Discover amplification loops |
| Proteomics | Protein interactions and modifications | Map ubiquitination networks |
| Reporter assays | NF-κB/IRF activation | High-throughput screening |
| Flow cytometry | Cytokine production in single cells | Immune cell profiling |
| CRISPR library screening | Enrichment of sgRNAs affecting TLR response | Novel regulator discovery |
| Imaging | Subcellular localization of signaling components | Dynamic pathway analysis |
| Bioinformatics | Pathway enrichment and network analysis | Integrate multi-omics data |
CRISPR knockout and knock-in
CRISPR-Cas9 knockout of candidate positive regulators followed by TLR ligand stimulation and cytokine profiling can establish causality. Knock-in of point mutations allows structure-function analysis of adaptors and kinases.
Transcriptomics and proteomics
RNA-seq after TLR stimulation reveals transcriptional amplification loops, such as IRF-7 induction. Proteomics can identify ubiquitination events and interactome changes.
Reporter assays and imaging
NF-κB or interferon reporter cell lines enable high-throughput screening of positive regulators. Live-cell imaging can track NF-κB nuclear translocation dynamics.
Functional genomics screens
Genome-wide CRISPR screens with TLR-induced reporter expression can identify novel amplifiers and negative regulators.
How CRISPR Can Be Used to Study GO:0034123 positive regulation of toll-like receptor signaling pathway
Knockout
CRISPR knockout of candidate genes in immune cell lines or primary cells can determine whether they are required for positive regulation of TLR signaling. For example, knocking out MYD88 abolishes MyD88-dependent TLR responses.
Point Mutation
Introducing point mutations in kinase domains or ubiquitin acceptor sites can dissect specific phospho-events that amplify TLR signaling. This is useful for studying IRAK4 or TBK1 activation mechanisms.
Knock-in
Knock-in of tagged versions of adaptors (e.g., HA-TRAF6) enables interaction studies and live-cell imaging. Knock-in of disease-associated variants can model human inflammatory disorders.
Overexpression
Overexpression of positive regulators such as IRF-7 can enhance type I interferon responses, providing gain-of-function models. This is valuable for vaccine adjuvant research.
How EDITGENE Supports positive regulation of toll-like receptor signaling pathway Research
Researchers studying positive regulation of toll-like receptor signaling pathway-related genes often need to determine whether a candidate gene is causally involved in amplifying or dampening TLR responses. EDITGENE provides comprehensive CRISPR services to accelerate this discovery.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of toll-like receptor signaling pathway research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| HSP90B1 Knockout HEK293 Cell Line | EDJ-KQ199 | Human | 7184 | Details Get a Quote |
| GDI1 Knockout HEK293 Cell Line | EDJ-KQ3928 | Human | 2664 | Details Get a Quote |
| LRCH4 Knockout HEK293 Cell Line | EDJ-KQ5142 | Human | 4034 | Details Get a Quote |
| LRCH4 Knockout A-549 Cell Line | EDJ-KQ28103 | Human | 4034 | Details Get a Quote |
| LRCH4 Knockout HCT 116 Cell Line | EDJ-KQ28104 | Human | 4034 | Details Get a Quote |
| LRCH4 Knockout HeLa Cell Line | EDJ-KQ28105 | Human | 4034 | Details Get a Quote |
| HSP90B1 Knockout A-549 Cell Line | EDJ-KQ19540 | Human | 7184 | Details Get a Quote |
| HSP90B1 Knockout HCT 116 Cell Line | EDJ-KQ19541 | Human | 7184 | Details Get a Quote |
| HSP90B1 Knockout HeLa Cell Line | EDJ-KQ19542 | Human | 7184 | Details Get a Quote |
| GDI1 Knockout A-549 Cell Line | EDJ-KQ27403 | Human | 2664 | Details Get a Quote |
| GDI1 Knockout HCT 116 Cell Line | EDJ-KQ27404 | Human | 2664 | Details Get a Quote |
| GDI1 Knockout HeLa Cell Line | EDJ-KQ27405 | Human | 2664 | Details Get a Quote |
Displaying Records 1 To 12 Of 12 Records
Frequently Asked Questions About positive regulation of toll-like receptor signaling pathway
What is GO:0034123?
GO:0034123 is the Gene Ontology term for positive regulation of toll-like receptor signaling pathway, describing processes that enhance TLR signal transduction.
What genes are involved in positive regulation of TLR signaling?
Key genes include MYD88, TIRAP, TRIF, TRAM, IRAK4, IRAK1, TRAF6, TAK1, TBK1, IKKε, and IRF7.
How does IRF-7 amplify TLR signaling?
IRF-7 is a master transcription factor that induces type I interferon genes, creating a positive feedback loop downstream of TLR7/9.
What diseases are linked to dysregulated TLR positive regulation?
Inflammatory diseases, autoimmune conditions, myeloproliferative neoplasms, and severe viral infections.
How can CRISPR help study positive regulation of TLR signaling?
CRISPR knockout, knock-in, and overexpression models allow causal testing of candidate regulators in immune cells.
What is the role of TRAF6 in TLR signaling?
TRAF6 is an E3 ubiquitin ligase that catalyzes K63-linked polyubiquitination, scaffolding downstream kinase activation.
What are negative regulators of TLR signaling?
A20 (TNFAIP3), SOCS1, and IRAK3 are negative regulators that prevent excessive TLR activation.
How is TLR signaling studied in hematopoietic cells?
Using CRISPR-edited hematopoietic stem and progenitor cells followed by TLR stimulation and functional assays.
What is the evolutionary significance of TLR signaling genes?
TLR signaling genes show distinct evolutionary patterns in cetaceans and bony fish, reflecting adaptation to pathogens.
Can the microbiome influence TLR signaling?
Yes, the microbiome regulates neutrophil ageing via TLR signaling, demonstrating environmental control.
Conclusion
GO:0034123, positive regulation of toll-like receptor signaling pathway, is a fundamental biological process that amplifies innate immune responses. Its tight control is essential for host defense, and its dysregulation contributes to inflammatory and neoplastic diseases. Advances in CRISPR genome editing and functional genomics now enable precise dissection of positive regulators, offering new therapeutic opportunities.
References
- 1. O'Neill LA. 2008. When signaling pathways collide: positive and negative regulation of toll-like receptor signal transduction.. Immunity 29(1):12-20 PMID: 18631453
- 2. Tian R et al.. 2019. Distinct evolution of toll-like receptor signaling pathway genes in cetaceans.. Genes Genomics 41(12):1417-1430 PMID: 31535317
- 3. Zhang D et al.. 2015. Neutrophil ageing is regulated by the microbiome.. Nature 525(7570):528-32 PMID: 26374999
- 4. Muzio M et al.. 2000. Toll-like receptors.. Microbes Infect 2(3):251-5 PMID: 10758401
- 5. Honda K et al.. 2005. IRF-7 is the master regulator of type-I interferon-dependent immune responses.. Nature 434(7034):772-7 PMID: 15800576
- 6. Lai HY et al.. 2019. Defective negative regulation of Toll-like receptor signaling leads to excessive TNF-α in myeloproliferative neoplasm.. Blood Adv 3(2):122-131 PMID: 30647074
- 7. Rebl A et al.. 2010. Toll-like receptor signaling in bony fish.. Vet Immunol Immunopathol 134(3-4):139-50 PMID: 19850357
- 8. Capitano ML. 2019. Toll-like receptor signaling in hematopoietic stem and progenitor cells.. Curr Opin Hematol 26(4):207-213 PMID: 31033704
